Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
August 11, 2016 08:00 ET
|
Advaxis
AXAL meets stage 1 primary objective, demonstrates increased systemic HPV-reactive T-cell responsesPRINCETON, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage...
Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
July 26, 2016 08:00 ET
|
Advaxis
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck...
Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients
July 21, 2016 07:00 ET
|
Advaxis
PRINCETON, N.J., July 21, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and...
European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
July 18, 2016 07:30 ET
|
Advaxis
PRINCETON, N.J., July 18, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm...
Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
July 12, 2016 08:00 ET
|
Advaxis
PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined...
Advaxis to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
July 08, 2016 08:00 ET
|
Advaxis
PRINCETON, N.J., July 08, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O’Connor,...
FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
July 06, 2016 07:00 ET
|
Advaxis
Enrollment to commence this summer PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today...
Advaxis to Webcast Investor & Analyst Day 2016
June 27, 2016 08:00 ET
|
Advaxis
PRINCETON, N.J., June 27, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that their annual Investor...
Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
June 08, 2016 08:00 ET
|
Advaxis
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer PRINCETON, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage...
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
June 06, 2016 07:00 ET
|
Advaxis
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumabPRINCETON, N.J., June 06, 2016...